Cingulate receives first US patent for ADHD drug CTx-1301 through Dec 2042

Cingulate Inc.

USPTO issued Patent No. 12,653,791 covering CTx-1301 formulation and method of use through Dec 2042.
First company-owned US patent for lead ADHD asset; includes composition-of-matter and method-of-treatment claims.
Cingulate holds additional patents in 30 European territories, Australia, Canada, Israel; applications pending in Hong Kong and South Korea.
CTx-1301 is a once-daily trimodal tablet using Precision Timed Release platform; being developed under FDA 505(b)(2) pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.